Upstream Bio, Inc. (UPB)
NMS · Healthcare · Biotechnology
$5.73
-0.35%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$313.8M
Shares Outstanding
54.8M
P/S (TTM)
99.4x
Exchange
NMS
Currency
USD
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 683K | 668K | 1.0M | 773K |
| Operating Income | (37.8M) | (46.2M) | (43.6M) | (42.4M) |
| Net Income | (33.7M) | (42.5M) | (40.6M) | (39.7M) |
| Diluted EPS | $-0.63 | $-0.78 | $-0.75 | $-0.72 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.2M | 2.4M | 2.4M | 2.9M |
| Operating Income | (23.9M) | (40.1M) | (77.8M) | (160.4M) |
| Net Income | (23.9M) | (20.5M) | (62.8M) | (143.4M) |
| Diluted EPS | $-0.66 | $-1.05 | $-1.17 | $-2.66 |